source
- Moderna’s melanoma vaccine trial success sparks $45 billion market value surgeModerna’s shares jumped more than 170% after the company announced that its experimental melanoma vaccine, intismeran, met its primary goals in a Phase 3 trial. The surge added roughly $45 billion…
- Lilly partners with Amplitude on vaccines; Otsuka scraps psychedelic trialPlus news about AC Immune, Lilly's Adverum and SiranBio. 🤝 Eli Lilly signs vaccine deal with Amplitude: The companies will work to develop vaccines using “trans-amplifying RNA,” or taRNA, for infe…Endpoints · 2h ago↗ source